NewAmsterdam Pharma Company N.V. (NAMS)

NASDAQ: NAMS · USD

$21.1

+0.59 (+2.9%)· Recorded snapshot

Market cap	2.5B
Revenue (ttm)	7.1M
Net income (ttm)	-259.5M
EPS (ttm)	-$2.14
Shares out	119.5M
Volume	1,279,473
Beta	0.10

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 7.1M
Net income (ttm): -259.5M
EPS (ttm): -$2.14
Market cap: 2.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-36.8

P25 n/aP50 n/aP75 n/a

ROIC-21.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NAMS indicators

Market & fundamental data

Available fields

194

Groups with data

Currency

USD

Showing 194 of 194 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001936258
Company name	NewAmsterdam Pharma Company N.V.
Country	Netherlands
Country code	US
Earnings date	2026-11-09
Earnings time	bmo
Employees	100
Employees change	32
Employees growth	47.06%
Enterprise value	$1.8B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2019
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	NL00150012L7
Last 10-K release date	2026-02-18
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$2.5B
Market cap category	Mid-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$21.09
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	NAMS
Website	https://www.newamsterdampharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-10.17%
EV/Sales	246.79x
FCF / EV yield	-8.18%
FCF yield	-5.9%
Forward EV/Sales	62.32x
Forward P/S	86.37x
P/B ratio	3.82x
P/S ratio	342.03x
Price / tangible book value	3.86x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-3,432.2%
Pretax margin	-3,644.21%
Profit per employee	$-2.6M
Revenue per employee	$71,210
ROA	-20.11%
ROA (5Y)	-23.93%
ROCE	-38.7%
ROE	-36.81%
ROE (5Y)	-58.41%
ROIC	-21.66%
SBC / revenue	918.64%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Gross profit growth	-88.87%
Gross profit growth (Q)	-80.67%
Gross profit growth 3Y	-13.4%
Net income growth years	1
Revenue growth	-88.87%
Revenue growth (Q)	-80.67%
Revenue growth (QoQ)	21.74%
Revenue growth 3Y	-13.4%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-260,000
Depreciation and amortization	$244,000
EBIT	$-244.4M
EBITDA	$-244.2M
EPS	$-2.14
FCF per share	$-1.20
Financing cash flow	$41.7M
Free cash flow	$-143.7M
Free cash flow minus SBC	$-209.1M
Gross profit	$7.1M
Investing cash flow	$-34.9M
Net cash flow	$-138.4M
Net income	$-259.5M
Operating cash flow minus SBC	$-208.9M
Operating income	$-244.4M
Revenue	$7.1M
Stock-based compensation	$65.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	27.61
Book value per share	$5.37
Debt / equity	0
Long-term assets	$45.2M
Long-term liabilities	$56,000
Net cash (debt)	$678.2M
Net cash / market cap	27.84%
Net cash growth	-13.39%
Net debt / equity	-1.07
Piotroski F-Score	1
Property, plant and equipment	$493,000
Shareholders' equity	$631.4M
Tangible book value	$631.1M
Tangible book value per share	$5.36
Total assets	$704.5M
Total cash	$633.9M
Total debt	$82,000
Total liabilities	$73M
WACC	4.8%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.01
Current assets	$659.2M
Current liabilities	$73M
Current ratio	9.03
Net working capital	$-47.6M
Quick ratio	8.76
Working capital	$586.2M
Working capital turnover	0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-12.87%
Dividend yield	0%
Shareholder yield	-12.87%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$29.06
1D price change	2.88%
1M price change	-8.77%
1M total return	-8.77%
1W price change	-4.19%
1W total return	-4.19%
1Y price change	-42.84%
1Y return CAGR	-42.86%
1Y total return	-42.84%
20-day SMA	$21.23
200-day SMA	$29.91
3M price change	-31.83%
3M total return	-31.83%
3Y price change	207.46%
3Y return CAGR	45.4%
3Y total return	207.46%
50-day SMA	$23.16
50-day SMA vs 200-day SMA	50under200
52-week high	$42.21
52-week high date	2026-05-11
52-week low	$19.13
52-week low date	2026-10-23
5Y price change	109.99%
5Y return CAGR	16%
5Y total return	109.99%
6M price change	-32.35%
6M total return	-32.35%
All-time high	$42.21
All-time high date	2026-05-11
All-time low	$5.63
All-time low date	2023-10-26
Average true range (ATR)	$1.21
Average volume	1.4M
Beta (1Y)	1.47
Beta (2Y)	1.45
Beta (5Y)	0.1
Change from 52-week high	-50.03%
Change from 52-week low	10.25%
Change from all-time high	-51.19%
Change from all-time low	265.7%
Change from open	3.69%
Day's gap	-0.78%
Dollar volume	$27M
High price	$21.11
Low price	$20.20
Monthly RSI	43.5
Open price	$20.34
Position in 52-week range	97.8%
Premarket change	-0.54%
Premarket close	$20.50
Premarket price	$20.39
Premarket volume	1.1K
Previous close	$20.50
Price vs 150-day SMA	-29.12%
Price vs 20-day SMA	-2.99%
Price vs 200-day SMA	-31.14%
Price vs 50-day SMA	-11.06%
Relative volume	0.91
RSI	43.02
Sharpe ratio	-0.86
Sharpe ratio (3Y)	0.84
Sharpe ratio (5Y)	0.47
Sortino ratio	-1.1
Sortino ratio (3Y)	1.59
Sortino ratio (5Y)	0.89
Volume	1.3M
Weekly RSI	34.89
YTD price change	-41.28%
YTD total return	-41.28%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	81.5M
Float percentage	68.18%
Shares change (QoQ)	1.36%
Shares change (YoY)	12.87%
Shares held by insiders	0.89%
Shares held by institutions	75.16%
Shares outstanding	119.5M
Short % of shares	18.64%
Short ratio	10.4 days

Deeper analysis on NAMS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NAMS report

Is a complete NAMS research report available?

No complete published report is available for NewAmsterdam Pharma Company N.V. (NAMS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

NewAmsterdam Pharma Company N.V. (NAMS)

Price

Financial snapshot

Fair-value bridge

Latest news · NAMS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NAMS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NAMS

Frequently asked questions